Eli Lilly

News

Novo Nordisk, Lilly highlight oral obesity drugs at ADA

New data from Novo Nordisk’s phase 3 trial of an oral, high-dose formulation of semaglutide reinforces its potential as a weight-loss therapy in obesity, but Eli Lilly is

News

Jardiance is first SGLT2 given FDA OK for use in children

With rates of juvenile type 2 diabetes rocketing in the US, doctors now have access to an alternative oral therapy – the first new oral option for more than 20 years.

News

Lilly bets $2.4bn on Dice’s immune disease platform

Eli Lilly has struck a $2.4 billion deal to buy Dice Therapeutics and its drug discovery and development platform for oral, small molecule therapies for immunological dise

News

Weight-loss drugs ‘will be a $60bn market in 10 years’

Frantic demand for drugs to treat obesity from Novo Nordisk, Eli Lilly, and others could support a global market worth an eye-watering $60 billion within the next decade,

News

ASCO: Novartis touts Kisqali adjuvant breast cancer data

Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reporte

News

CMS update on Alzheimer's coverage raises questions

The Centres for Medicare and Medicaid Services (CMS) has formally announced its intention to allow coverage of new amyloid-targeting drugs for Alzheimer’s disease if they

Novo Nordisk, Lilly highlight oral obesity drugs at ADA

Jardiance is first SGLT2 given FDA OK for use in children

Lilly bets $2.4bn on Dice’s immune disease platform

Weight-loss drugs ‘will be a $60bn market in 10 years’

ASCO: Novartis touts Kisqali adjuvant breast cancer data

CMS update on Alzheimer's coverage raises questions

Europe is facing a surge in STIs, says ECDC

Discover a new era of healthcare panel engagement: Grounded ...

Eli Lilly

Editor's Picks